The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessPalantir’s premium valuation raises a tougher question for shareholders: what exactly is being priced inThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex Times
Back to front
UnitedHealth coverage decision boosts Guardant’s Shield blood test for colorectal cancer screening
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 2, 12:37 PM EDT

UnitedHealth coverage decision boosts Guardant’s Shield blood test for colorectal cancer screening

Guardant Health said UnitedHealth will cover its Shield blood test for average-risk adults, marking the first time a major private U.S. insurer has reimbursed a liquid biopsy approach for primary colorectal cancer screening.

By The Apex Times Newsroom2 min readAI-assisted Apex article

UnitedHealth’s coverage decision for Guardant Health’s Shield blood test for colorectal cancer is being hailed by industry analysts as a turning point for blood-based screening, a category that is often framed as a more convenient alternative to stool testing.

Guardant Health said Wednesday that Shield, which is designed for colorectal cancer screening in average-risk adults, is now covered by UnitedHealth. The company said the payer’s move expands access to the screening to about 100 million Americans.

The Shield test is intended for people who are not considered high risk for colorectal cancer. Guardant said patients with a positive Shield result are referred for colonoscopy evaluation, which remains the “gold standard” for colorectal cancer screening.

Shield is positioned as a liquid biopsy. Rather than collecting stool for at-home testing, the test can be completed with a blood draw during a routine doctor’s visit, according to Guardant’s description relayed in the announcement. The test uses methylation partitioning of cell-free DNA, looking for alterations associated with colorectal cancer in the blood.

The Shield test is also described as the first blood test approved by the U.S. Food and Drug Administration for primary colorectal cancer screening in average-risk adults age 45 and older. That approval, combined with UnitedHealth’s decision to reimburse it, is what prompted analysts to characterize the coverage as unusually consequential for the broader shift toward blood-based detection methods.

Canaccord Genuity analyst Kyle Mikson called the coverage a “watershed moment” for liquid biopsy-based cancer screening and for blood-based cancer testing more generally. The analysis also pointed to the fact that Guardant’s test received coverage from a major commercial payer before it appeared in the U.S. Preventive Services Task Force guidance, implying a perceived unmet need in the market.

Guardant framed the UnitedHealth coverage as a milestone in its commercial expansion. Co-CEO AmirAli Talasaz said the coverage will make the test more accessible and comes as colorectal cancer rates in younger people are rising, according to the company statement referenced in the report.

Still, the details released publicly around the reimbursement change are limited. The announcement and the related reporting did not spell out coverage criteria beyond the average-risk screening indication, nor did it provide information on whether additional prior authorization, benefit design, or exclusions apply across UnitedHealth’s commercial and managed-care lines. Guardant and UnitedHealth also did not specify the expected near-term volume or financial impact in the coverage announcement described in the report.

Why It Matters

  • Insurance reimbursement is often the gatekeeper for adoption of new diagnostics, and UnitedHealth’s move could accelerate patient access beyond self-pay or limited clinical use.
  • If coverage translates into increased screening participation, it may change how providers and health systems balance convenience with follow-up testing requirements like colonoscopy.
  • The decision adds momentum to blood-based approaches in cancer screening, an area where payers have historically been cautious due to evidence thresholds and cost considerations.
  • The timing relative to formal preventive guidance suggests payers may be acting on clinical readiness and real-world demand before guideline committees fully incorporate new tests.

Sources

Key Facts

  • Guardant Health said its Shield blood test for colorectal cancer screening is now covered by UnitedHealth.
  • The coverage is described as the first major private U.S. health insurer reimbursement for Shield, a blood-based approach for primary colorectal cancer screening.
  • Shield is characterized as the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults age 45 and older.
  • Shield can be performed using a blood draw during a routine doctor’s visit, as an alternative to stool-based testing.
  • The test is for average-risk patients, and positive results are referred for colonoscopy evaluation.
  • Guardant said UnitedHealth’s coverage expands access to about 100 million Americans.
  • An analyst described the coverage as a “watershed moment” for liquid biopsy-based cancer screening and blood-based cancer testing.

Healthcare Related

UnitedHealth coverage decision boosts Guardant’s Shield blood test for colorectal cancer screening | The Apex Times